Cargando…

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs

BACKGROUND: A small number of individuals with B-cell-related primary immunodeficiency diseases (PIDs) may exhibit long-term (prolonged or chronic) excretion of immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) following infection with oral poliovirus vaccine (OPV). These individuals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duintjer Tebbens, Radboud J., Pallansch, Mark A., Thompson, Kimberly M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574619/ https://www.ncbi.nlm.nih.gov/pubmed/26382043 http://dx.doi.org/10.1186/s12879-015-1115-5

Ejemplares similares

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
por: DUINTJER TEBBENS, R. J., et al.
Publicado: (2017)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2017)

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2015)

How should we prepare for an outbreak of reintroduced live polioviruses?
por: Thompson, Kimberly M, et al.
Publicado: (2017)

An economic analysis of poliovirus risk management policy options for 2013–2052
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination
por: Kalkowska, Dominika A, et al.
Publicado: (2015)

Another look at silent circulation of poliovirus in small populations
por: Kalkowska, Dominika A., et al.
Publicado: (2018)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2019)

Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters
por: Kalkowska, D. A., et al.
Publicado: (2019)

Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission
por: Thompson, Kimberly M., et al.
Publicado: (2017)

Inferring Numbers of Wild Poliovirus Excretors Using Quantitative Environmental Surveillance
por: Perepliotchikov, Yuri, et al.
Publicado: (2021)

Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2019)

The potential impact of expanding target age groups for polio immunization campaigns
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2014)

Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States
por: Marin, Mona, et al.
Publicado: (2017)

Outbreak response strategies with type 2-containing oral poliovirus vaccines ()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995–2014
por: Shaghaghi, Mohammadreza, et al.
Publicado: (2016)

Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency virus infected children in Kenya
por: Khetsuriani, Nino, et al.
Publicado: (2009)

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal()
por: Harutyunyan, Vachagan, et al.
Publicado: (2023)

Emergence of Vaccine-derived Polioviruses, Democratic Republic of Congo, 2004–2011
por: Gumede, Nicksy, et al.
Publicado: (2013)

Asymptomatic immunodeficiency-associated vaccine-derived poliovirus infections in two UK children
por: Singanayagam, Anika, et al.
Publicado: (2023)

Immunodeficiency-associated Vaccine-Derived Poliovirus Type 3 in Infant, South Africa, 2011
por: Gumede, Nicksy, et al.
Publicado: (2012)

Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses — Worldwide, July 2018–December 2019
por: Macklin, Grace, et al.
Publicado: (2020)

The Molecular Evolution of Type 2 Vaccine-Derived Polioviruses in Individuals with Primary Immunodeficiency Diseases
por: Kitamura, Kouichi, et al.
Publicado: (2021)

Interim CDC Guidance for Polio Vaccination for Travel to and from Countries Affected by Wild Poliovirus
por: Wallace, Gregory S., et al.
Publicado: (2014)

Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–June 2019
por: Jorba, Jaume, et al.
Publicado: (2019)

Costs of Illness Due to Cholera, Costs of Immunization and Cost-Effectiveness of an Oral Cholera Mass Vaccination Campaign in Zanzibar
por: Schaetti, Christian, et al.
Publicado: (2012)

Potential Future Use, Costs, and Value of Poliovirus Vaccines
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians’ perspectives in the endgame plan for polio eradication
por: Galal, Nermeen M., et al.
Publicado: (2018)

A Survey to Assess Serological Prevalence of Poliovirus Antibodies in Areas With High-Risk for Vaccine-Derived Poliovirus Transmission in Chad
por: Gamougam, Kadidja, et al.
Publicado: (2021)

Are Circulating Type 2 Vaccine-derived Polioviruses (VDPVs) Genetically Distinguishable from Immunodeficiency-associated VDPVs?
por: Zhao, Kun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1kunkr8vuvsahrpvmb857ea80k